Literature DB >> 2408970

(2'-5') oligo adenylate synthetase activity in leucocytes of patients with inflammatory bowel disease.

R Stalnikowicz, K Goder, F Karmeli, C Fiocchi, D Rachmilewitz.   

Abstract

The activity of an interferon induced enzyme, (2',5') oligo adenylate synthetase, was determined in peripheral blood mononuclear cells and granulocytes of patients with inflammatory bowel disease and compared with its activity in cells isolated from normal subjects. In spite of the fact that circulating interferon is detected in patients with inflammatory bowel disease, we failed to see any increase in (2',5') oligo adenylate synthetase activity in these patients. The mean +/- SE enzyme activity given in nmol ATP incorporated into (2',5') isoadenylate oligomers by extracts of 10(5) peripheral blood mononuclear cells/21 hours was in normal subjects 1.84 +/- 0.30 (n = 27), in patients with active Crohn's disease 1.38 +/- 0.15 (n = 20) and in patients with active ulcerative colitis 1.14 +/- 0.23 (n = 21). (2',5') oligo adenylate synthetase activity in granulocytes was also similar in normal subjects and in patients with active ulcerative colitis or Crohn's disease. The enzyme activity in patients with active disease was similar both prior to and during steroid therapy. The low (2',5') oligo adenylate synthetase activity in peripheral blood mononuclear cells and granulocytes of patients with active inflammatory bowel disease may reflect decreased cellular response to interferon or a difference in the type of interferon elevated in viral diseases and in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2408970      PMCID: PMC1432768          DOI: 10.1136/gut.26.6.556

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Circulating immune complexes and disease activity in Crohn's disease.

Authors:  R Fiasse; A Z Lurhuma; C L Cambiaso; P L Masson; C Dive
Journal:  Gut       Date:  1978-07       Impact factor: 23.059

2.  Decreased suppressor cell activity in inflammatory bowel disease.

Authors:  H J Hodgson; J R Wands; K J Isselbacher
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

3.  Time and dosage dependence of immunoenhancement by murine type II interferon preparations.

Authors:  G Sonnenfeld; A D Mandel; T C Merigan
Journal:  Cell Immunol       Date:  1978-10       Impact factor: 4.868

4.  Increased levels of (2'-5')oligo(A) polymerase activity in human lymphoblastoid cells treated with glucocorticoids.

Authors:  I Krishnan; C Baglioni
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

5.  Natural killer cells: characteristics and regulation of activity.

Authors:  R B Herberman; J Djeu; H D Kay; J R Ortaldo; C Riccardi; G D Bonnard; H T Holden; R Fagnani; A Santoni; P Puccetti
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

6.  Impaired natural killer cell activity in patients with inflammatory bowel disease: evidence for a qualitative defect.

Authors:  C H Ginsburg; J T Dambrauskas; K A Ault; Z M Falchuk
Journal:  Gastroenterology       Date:  1983-10       Impact factor: 22.682

7.  Conversion of the reactive sulfhydryl groups of proteins to the S-trifluoroethyl derivatives. Application to human hemoglobin.

Authors:  F C Knowles
Journal:  Anal Biochem       Date:  1981-01-01       Impact factor: 3.365

8.  Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells.

Authors:  D Wallach; M Fellous; M Revel
Journal:  Nature       Date:  1982-10-28       Impact factor: 49.962

9.  Assay of an interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases.

Authors:  A Schattner; D Wallach; G Merlin; T Hahn; S Levin; M Revel
Journal:  Lancet       Date:  1981-09-05       Impact factor: 79.321

10.  Evaluation of the human interferon system in viral disease.

Authors:  S Levin; T Hahn
Journal:  Clin Exp Immunol       Date:  1981-12       Impact factor: 4.330

  10 in total
  4 in total

1.  The role of interferon gamma in the pathogenesis of Crohn's disease.

Authors:  T Sasaki; N Hiwatashi; H Yamazaki; M Noguchi; T Toyota
Journal:  Gastroenterol Jpn       Date:  1992-02

Review 2.  Production of inflammatory cytokines in the intestinal lamina propria.

Authors:  C Fiocchi
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

3.  Enteropathogenic Escherichia coli inhibits type I interferon- and RNase L-mediated host defense to disrupt intestinal epithelial cell barrier function.

Authors:  Tiha M Long; Shahista Nisa; Michael S Donnenberg; Bret A Hassel
Journal:  Infect Immun       Date:  2014-04-14       Impact factor: 3.441

4.  Interferon gamma production by human intestinal mucosal mononuclear cells. Decreased levels in inflammatory bowel disease.

Authors:  B Y Lieberman; C Fiocchi; K R Youngman; W K Sapatnekar; M R Proffitt
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.